The short version.
The age-related GH decline is real and well-documented. Peak GH secretion happens in adolescence; by your 30s it's lower; by your 50s it's substantially lower. The phenomenon — sometimes called somatopause — involves both reduced GH pulse amplitude and reduced sensitivity at the receptor level.
Sermorelin, a GHRH analog, is one of the more common tools used in adults over 50 who want to support endogenous GH signaling without the side-effect profile of full-dose recombinant human GH. The premise: rather than replacing the hormone, restore the signal that drives the body's own pulsatile release.
What the literature actually says.
Sermorelin and other GHRH analogs have been studied in adults with GH deficiency and in healthy older adults. Modest improvements in body composition (lean mass up, fat mass down), sleep architecture, and IGF-1 levels appear consistently across studies, though effect sizes are smaller than what you'd see with high-dose rhGH.
The trade-off is part of the appeal: sermorelin's reliance on endogenous pulsatile release means it can't drive IGF-1 to the supraphysiologic levels associated with rhGH side effects (insulin resistance, edema, joint pain). The negative-feedback loop is preserved.
The honest framing: sermorelin is a reasonable choice for adults over 50 who've characterized the rest of their hormonal picture (testosterone, thyroid, cortisol patterns) and want to support GH signaling without going to rhGH. It's not a fountain of youth. The effects are modest, real, and slow.
Sermorelin restores the signal. It doesn't replace the hormone. That distinction is most of the safety story.
Why oversight matters.
The internet sells almost any peptide as research chemicals — vials with disclaimers, no prescription, no provider, no follow-up. The risk isn't theoretical. Sterility, peptide identity, peptide content, and contamination all vary widely between gray-market vendors. The FDA has been explicit that compounded drugs aren't FDA-approved, and that research-only labels don't protect consumers when products end up in human use.
Oversight isn't a bureaucratic checkbox. It's a U.S.-licensed prescriber who reviews your history before prescribing, a 503A compounding pharmacy that sources active pharmaceutical ingredient and prepares the medication under USP 797 sterile standards, and a follow-up cadence that lets someone catch a problem before it becomes a worse one.
How Boswell handles this.
Boswell pairs you with a U.S.-licensed physician for the intake. They review your goals, medications, history, and any contraindications before prescribing. If a protocol isn't appropriate, you don't get it. If it is, the prescription goes to a 503A compounding pharmacy that prepares the medication under sterile compounding standards, labels it for you specifically, and ships it directly.
Refills aren't automatic — they involve a check-in. The point isn't to gate access; it's to keep someone clinical in the loop while you're on therapy. How Boswell works →
Questions worth asking your provider.
- Have we characterized testosterone, thyroid, and IGF-1 before adding sermorelin?
- What's the realistic timeline — 8 weeks, 12, longer — before we reassess?
- Does my history (prior cancer, diabetes, retinopathy) make this inappropriate?
- How will we tell if I'm responding versus not?
- Does CJC-1295/ipamorelin fit my profile better?
Sources